Genetics Newswire
1 - Idaho Technology Expands Its High Resolution Melting Patent Portfolio
SALT LAKE CITY-(Business Wire)-September 29, 2009 - Idaho Technology’s patent portfolio continues to grow as the U.S. Patent and Trademark Office granted the company U.S. Patent No. 7,582,429 relating to methods of performing genetic analysis in the presence of a double-stranded nucleic acid...
2 - Celera to Webcast Presentation at JMP Securities 2009 Healthcare Conference
ALAMEDA, Calif.-(Business Wire)-September 29, 2009 - Celera Corporation (NASDAQ:CRA) announced today that it will webcast its presentation at the JMP Securities 2009 Healthcare conference on Tuesday, October 6, 2009. The live webcast is scheduled to begin at 10:00 am ET. Ugo DeBlasi, Chief Financial...
3 - Personalized, Gene-Based Risk Testing For Lung Cancer Gives New Tool To Help Smokers Quit
PHILADELPHIA-(Business Wire)-September 29, 2009 - Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd. The...
4 - ABL and Evivar Medical Enter into Agreements to Form a Global Strategic Partnership and IP Cross-Licensing for Disease Management and Personalized Healthcare of Hepatitis B and HIV Infections
LUXEMBOURG & MELBOURNE, Australia-(Business Wire)-September 29, 2009 - ABL, S.A. and Evivar Medical Pty Ltd today announced the completion of agreements to cross-licence their respective intellectual property portfolios and to form strategic alliances based on the use of their proprietary...
5 - Top Life Sciences Attorney to Join Intrexon as Chief Legal Officer
BLACKSBURG, Va.-(Business Wire)-September 29, 2009 - Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the appointment of Asher M. Rubin as Executive Vice President, Chief Legal Officer...
6 - Luminex Corporation Hosts Seventh Annual Planet xMAP Europe
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it will host Planet xMAP Europe 2009, its annual European multiplexing technology symposium, October 7-8, 2009, at Beurs van Berlage in Amsterdam. The program for Planet xMAP Europe 2009...
7 - Bio Japan 2009: The Biggest Biotechnology Event in Japan.
YOKOHAMA, Japan-(Business Wire)-September 29, 2009 - We would like to thank you sincerely for your understanding and ongoing cooperation for BioJapn. With your wholehearted support, BioJapan has been progressing successfully in both its contents and scale every year. This year, we are aiming to...
8 - Pluristem Therapeutics Has Been Selected to Present at The Israeli Presidential Conference 2009: Facing Tomorrow, Based on the Company’s Proprietary Technology and the Potential to Shape The Future of the Stem Cell Industry
HAIFA, Israel-(Business Wire)-September 29, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced it has been selected as one of the Israeli innovators in the stem cell field to present at The Israeli Presidential Conference 2009: Facing Tomorrow – Tomorrow's Industries...
9 - Life Technologies Foundation Awards $1.7 Million in Grants to Advance Science
CARLSBAD, Calif.-(Business Wire)-September 29, 2009 - The Life Technologies Foundation, a non-profit arm of Life Technologies Corporation (NASDAQ: LIFE) dedicated to advancing science education and scientific discovery, has awarded approximately $1.7 million in new grants that include the creation...
10 - Computable Genomix Announces Contest For Genomics Researchers
MEMPHIS, Tenn.-(Business Wire)-September 29, 2009 - Memphis-based Computable Genomix today announced it will launch a contest on Oct. 1, 2009, to coincide with the release of GeneIndexer, the company’s next-generation Web-based text-mining tool. Publish or Perish will award a $10,000 grant to each...
11 - SAIC-Frederick and Roche Enter into a Research Collaboration on Technology Advancements for Cancer Gene Sequencing
MADISON, Wis.-(Business Wire)-September 29, 2009 - National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (NYSE: SAI), and Roche Applied Science, a division of Roche Diagnostics Corporation (SWX:RO) (SWX:ROG) (Pink...
12 - Scarab Genomics Introduces ScarabXpress™ T7lac, a unique E. coli expression strain
MADISON, Wis.-(Business Wire)-September 29, 2009 - ScarabXpress is the latest strain in the multiple-deletion series (MDS) of Scarab Genomics Clean Genome® E. coli. Based on the MDS™42 strain, ScarabXpress T7lac contains a chromosomal copy of the T7 RNA polymerase gene expressed from a unique...
13 - PPD Announces Third Quarter 2009 Earnings Release, Webcast and Conference Call
WILMINGTON, N.C.-(Business Wire)-September 29, 2009 - PPD, Inc. (Nasdaq: PPDI) will release its third quarter 2009 financial results on Tuesday, October 27, 2009, after the market closes. The earnings release will be available on the PPD Web site at http://www.ppdi.com, FirstCall and Business...
14 - Precision BioSciences Announces U.S. Patent Office Reexamination of Cellectis Patents Involved in Litigation
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 29, 2009 - Precision BioSciences, Inc. today announced that the United States Patent and Trademark Office (PTO) has granted Precision’s requests for inter partes reexamination of U.S. Patent Nos. 6,610,545 (the ‘545 patent) and 7,309,605...
15 - Correlagen Announces Acquisition of System from Helicos BioSciences
WALTHAM, Mass.-(Business Wire)-September 28, 2009 - Correlagen Diagnostics Inc., a leading provider of genetic testing for disease diagnosis, today announced the acquisition of a system from and a scientific collaboration with Helicos BioSciences Corporation (NASDAQ: HLCS). “We believe that the...
16 - Life Technologies and febit Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies
CARLSBAD, Calif. & HEIDELBERG, Germany-(Business Wire)-September 28, 2009 - febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted...
17 - Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference
CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare Focus...
18 - HRC Fertility Offers Gene Security Parental Control for Embryonic Safety
PASADENA, Calif.-(Business Wire)-September 24, 2009 - Over the past twenty-one years, HRC Fertility has focused on introducing and perfecting new procedures and techniques that are on the cutting edge of reproductive technology. Together with the American Society for Reproductive Medicine (ASRM...
19 - TRADE NEWS: Agilent Technologies, Shanghai Institute of Biological Sciences and Chinese Academy of Sciences Open Center for Systems Biology
SANTA CLARA, Calif. & SHANGHAI-(Business Wire)-September 24, 2009 - Agilent Technologies Inc. (NYSE:A) today announced the opening of the Shanghai Institute of Biological Sciences (SIBS)-Agilent Center for Systems Biology in Shanghai, China. The center will feature multiple technology...
20 - Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants at London Conference That Biomarkers Patented by His Company Promise to Revolutionize The Field of Molecular Diagnostics
SAVANNAH, Ga.-(Business Wire)-September 24, 2009 - Dr. Stephen Barnhill, Chairman and CEO, Health Discovery Corporation (OTCBB: HDVY) (“HDC”), a molecular diagnostics company, spoke at the “Biomarkers in Clinical Trials” Conference taking place in London, September 23-24, 2009. The...
21 - Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
BERLIN-(Business Wire)-September 24, 2009 - Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC...
22 - Helicos Announces First-Ever Direct Sequencing of Single Molecules of RNA
CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the publication of a landmark study in which Helicos’ True Single Molecule Sequencing (tSMS...
23 - Life Technologies Initiates Suit Against Illumina Alleging Patent Infringement
SAN DIEGO-(Business Wire)-September 24, 2009 - Illumina, Inc. (Nasdaq:ILMN) today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies...
24 - PsoriasisDX and HairDX To Present “Pharmacogenomics In Dermatology And Cosmetics” During EADV Congress
BERLIN & IRVINE, Calif.-(Business Wire)-September 23, 2009 - A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the...
25 - BioPharm America™ 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US
CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Over 700 leaders from the biotechnology and pharmaceutical industry gathered last week for the 2nd annual BioPharm America™ partnering conference, which saw delegates from 665 companies engage in 1579 one-to-one partnering...
26 - RainDance Expands Sequence Enrichment Solution Capabilities with 20,000 Amplicon Library and Whole Genome Amplification Protocol
PROVIDENCE, R.I.-(Business Wire)-September 23, 2009 - RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for health and human disease research, announced today it has expanded the capabilities of its Sequence Enrichment Solution to enable the resequencing...
27 - Perlegen Introduces BREVAGen™ Breast Cancer Risk Stratification Test
MOUNTAIN VIEW, Calif.-(Business Wire)-September 23, 2009 - Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S...
28 - LifeSensors, Inc. Obtains Worldwide, Exclusive License to High Affinity “Ubiquitin Traps”
MALVERN, Pa.-(Business Wire)-September 23, 2009 - LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed...
29 - Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries
NEW YORK-(Business Wire)-September 23, 2009 - Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world. This initiative is the first time a vaccine...
30 - Bio-Computing a Major Focus of 22nd Annual SC Conference
PORTLAND, Ore.-(Business Wire)-September 23, 2009 - SC09, the 22nd annual supercomputing conference, recognized as the premier international conference on high performance computing (HPC), networking, storage and analysis, will offer presentations, seminars and panels featuring a world-class...
31 - Genzyme Provides Update on Cerezyme and Fabrazyme Supply
CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these...
32 - Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
HAIFA, Israel-(Business Wire)-September 23, 2009 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment...
33 - Top 20 Pharma Firms to Hunt for Deals at BIO-Europe 2009
ZURICH & VIENNA-(Business Wire)-September 22, 2009 - In order to seek out new partnering opportunities, the top 20 big pharma companies will be in attendance on November 2–4 in Vienna, Austria for BIO-Europe 2009, the largest dedicated partnering conference in Europe. Teams of scouts from...
34 - Genetic Hair Loss Test Now Introduced In Australia Through HairDX Distribution Agreement With Advanced Hair Studio
IRVINE, Calif. & EAST MELBOURNE, VICTORIA, Australia-(Business Wire)-September 22, 2009 - Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and...
35 - PacifiCord Secures Sterile Cord Blood Collection Bag
IRVINE, Calif.-(Business Wire)-September 22, 2009 - Dedicated to serving the private cord blood banking needs of Southern California, PacifiCord (www.pacificord.com) today announced it has secured Pall Corporation’s sterile cord blood collection bag. Since April 2006, this industry-best sterile...
36 - TRADE NEWS: Agilent Technologies Adds Human Exon Kit to Next-Generation-Sequencing Target Enrichment Portfolio
PROVIDENCE, R.I.-(Business Wire)-September 22, 2009 - Agilent Technologies Inc. (NYSE:A) has chosen the Cambridge Health Institute’s Next-Generation Sequencing Analysis conference today to introduce its SureSelect Human All Exon Kit for target enrichment prior to next-generation DNA sequencing...
37 - Curis to Present at Maxim Group Growth Conference 2009
CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Maxim Group Growth Conference...
38 - Helicos Presents at Cold Spring Harbor Laboratories Personal Genomes and CHI Next Generation Sequencing Meetings
CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) provided updates on recent scientific findings and progress on Helicos’s technology initiatives. Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the CHI Next Generation...
39 - Mentor Capital, Inc. Completes 2nd Year Audit for OTCBB Move; Reporting $0.16 Per Share in Basic Earnings
SAN DIEGO-(Business Wire)-September 21, 2009 - Mentor Capital, Inc. (Pink Sheets:MNTR) completed its FY 2008 audit in preparation for filing a self-registration statement with the SEC and applying to move from the Pink Sheets to begin being quoted on the Over-the-Counter Bulletin Board system. The...
40 - BioForward Announces Winners of Biotechnology Vision Summit’s Emerging Company Showcase
MADISON, Wis.-(Business Wire)-September 21, 2009 - Six Wisconsin biotechnology companies have been selected the winners of the first Emerging Company Showcase. The showcase is part of the Biotechnology Vision Summit 2009, being held on Wednesday, Oct. 7, at the Madison Marriott West in Madison, Wis...
41 - Sloning Closes Growth Financing Round Led by LBBW Venture
PUCHHEIM, Germany-(Business Wire)-September 21, 2009 - Sloning BioTechnology GmbH, the worldwide leading supplier of combinatorial gene libraries, received additional investments from all of its institutional shareholders: HBM BioVentures, LBBW Venture, DEWB and KfW to finance the company’s...
42 - NABsys Expands Leadership Team with Appointment of Stan Rose to Board of Directors
PROVIDENCE, R.I.-(Business Wire)-September 21, 2009 - NABsys Inc. announced today that industry veteran and serial entrepreneur, Stan Rose, Ph.D., has been appointed to the company’s board of directors. Dr. Rose is the most recent addition to the leadership team at NABsys, which recently raised $4...
43 - Dicerna Pharmaceuticals to Present at 2009 Biologics Drug Delivery & Beyond Conference
WATERTOWN, Mass.-(Business Wire)-September 21, 2009 - Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNAi molecules, today announced that Sujit K. Basu...
44 - Biogen Idec Commences Tender Offer for Facet Biotech
CAMBRIDGE, Mass.-(Business Wire)-September 21, 2009 - Biogen Idec Inc. (NASDAQ:BIIB) announced today that FBC Acquisition Corp., its wholly owned subsidiary, has commenced a tender offer to acquire all of the outstanding shares of Facet Biotech Corporation (NASDAQ:FACT) for $14.50 per share in cash...
45 - PerkinElmer Launches Columbus™ 2.0 High Content Screening Platform for High-Volume Image Data Management and Analysis
BOSTON-(Business Wire)-September 21, 2009 - At the High Content Analysis East conference in Boston, PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the launch of the Columbus™ 2.0 platform, its flagship high content...
46 - Enzo Biochem and National Institutes of Health to Cooperate in Development of Enzo’s Novel Therapeutic Candidate for Treatment of Autoimmune Uveitis
NEW YORK-(Business Wire)-September 21, 2009 - Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel...
47 - Pacific Biosciences Expands Mission and Prepares for Commercialization
MENLO PARK, Calif.-(Business Wire)-September 21, 2009 - Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today provided a number of updates to its commercial strategy and progress. First...
48 - ZymoGenetics Appoints Dennis M. Miller, Ph.D., Senior Vice President, Research and Preclinical Development
SEATTLE-(Business Wire)-September 18, 2009 - ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Dennis M. Miller, Ph.D. has been promoted to the position of Senior Vice President of Research and Preclinical Development and will serve as a member of the company’s executive management...
49 - From Ancient Bones to the Future of DNA Technologies: Forensic Experts Gather for Exclusive Symposium on Human Identity
MADISON, Wis.-(Business Wire)-September 18, 2009 - The 20th International Symposium on Human Identification will highlight advances in DNA technology and explore controversial issues brought about by the expanded power and use of DNA typing. Over 600 forensic analysts from around the world will...
50 - Former Deputy FDA Commissioner John Norris Appointed Chief Operating Officer at Health Discovery Corporation
SAVANNAH, Ga.-(Business Wire)-September 18, 2009 - Health Discovery Corporation (OTCBB:HDVY), a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former...
51 - Dr. Kevin Krenitsky, President of Enzo Clinical Labs, to Present At 27th Annual Lab Institute
NEW YORK-(Business Wire)-September 18, 2009 - Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27th Annual Lab Institute ’09, sponsored by Washington G2 Reports, on September 23, 2009 in Arlington, Virginia. Dr...
52 - Seattle Genetics to Present at UBS Global Life Sciences Conference
BOTHELL, Wash.-(Business Wire)-September 17, 2009 - Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 UBS Global Life Sciences Conference on Tuesday, September 22, 2009, at 2:00 p.m. Eastern Time. The...
53 - The Bioscience Conference That Thinks Globally
COLUMBUS, Ohio-(Business Wire)-September 17, 2009 - On October 1 the 2009 BioOhio Annual Conference, “BioGPS: Global Positioning for Success,” will focus on the globalization of bioscience and the inherent growth opportunities for Ohio organizations. Conference topics will range from exporting...
54 - Hythiam Raises Approximately $7 Million in Registered Direct Offering
LOS ANGELES-(Business Wire)-September 17, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that it has entered into definitive agreements to sell 9,333,334 shares of its common stock at a price per share of $.75 to institutional investors pursuant to a registered direct offering, representing...
55 - Origin Agritech Limited Reaches Agreement for Novel Glyphosate-Tolerance Gene
BEIJING-(Business Wire)-September 17, 2009 - Origin Biotechnology, a wholly-owned subsidiary of Origin Agritech Limited (NASDAQ:SEED) announced it has reached an comprehensive, worldwide agreement with the Institute of Microbiology of the Chinese Academy of Sciences (CAS) and Sichuan Biotech...
56 - California Stem Cell and Stemina Biomarker Discovery Announce Collaboration to Validate Effectiveness of Human Embryonic Stem Cell-Derived Cardiomyocyte Progenitors for Use in Predictive Toxicology
IRVINE, Calif.-(Business Wire)-September 17, 2009 - Collaboration between California Stem Cell, Inc. (CSC) and Stemina Biomarker Discovery on a study using CSC’s 96-well CardioPlateTM containing high purity human embryonic stem cell (hESC)-derived cardiomyocyte progenitor cells, has demonstrated...
57 - JMP® Genomics Next-Gen Seminar to Be Held at Broad Institute
CARY, N.C.-(Business Wire)-September 17, 2009 - Next-generation genetic sequencing technology and its applications to groundbreaking scientific research will be the focus of a seminar sponsored by JMP Genomics and hosted by the Broad Institute of MIT and Harvard in Cambridge, MA, Thursday, Oct. 8...
58 - Enzo Biochem’s Life Sciences Unit Introduces Novel System for Simultaneous Live-Cell Imaging of Nuclear Components
FARMINGDALE, N.Y.-(Business Wire)-September 17, 2009 - Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial™ line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in...
59 - Navigenics Welcomes Michael Critelli to Board of Directors
FOSTER CITY, Calif.-(Business Wire)-September 17, 2009 - Navigenics, a leading personal genomics testing company, announced today that Michael J. Critelli has been appointed to its board of directors. Upon his retirement in February 2009, Mr. Critelli completed a nearly 30-year career at Pitney...
60 - Roche’s xCELLigence System and FuGENE® HD Transfection Reagent Minimize Cytotoxic Effects in the Detection of Bax-Induced Apoptosis
PENZBERG, Germany-(Business Wire)-September 17, 2009 - Transfection is a way to transiently or permanently deliver nucleic acids into eukaryotic cells to study functional effects in response to altered gene expression and for protein production. In a recent study (1) the xCELLigence System for...
61 - RainDance Technologies and CLC bio Collaborate to Develop Specialized Software Solutions for Targeted Resequencing
LEXINGTON, Mass. & AARHUS, Denmark-(Business Wire)-September 17, 2009 - RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment...
62 - World-Class Scholars to Use Evolutionary Theory in Search for Solutions to High-Risk Adolescent Behavior
TUCSON, Ariz.-(Business Wire)-September 17, 2009 - The Evolution Institute and the University of Arizona's Frances McClelland Institute for Children, Youth, and Families are co-hosting an invitation-only workshop at the university, Oct. 30 - Nov. 2, for world-renowned scholars who will apply...
63 - EBD Group and Defined Health Form an Alliance on Conference Content
CARLSBAD, Calif. & ZURICH, Switzerland & FLORHAM PARK, N.J.-(Business Wire)-September 16, 2009 - EBD Group and Defined Health today announced the formation of an alliance that will help biopharmaceutical firms gain the insights they need to create and execute successful strategy. Under...
64 - Alnylam to Webcast Presentation at UBS Global Life Sciences Conference
CAMBRIDGE, Mass.-(Business Wire)-September 16, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 12:00 p.m. ET at the...
65 - Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial
SUNRISE, Fla.-(Business Wire)-September 16, 2009 - Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine...
66 - Aid Comes to UTMB Researchers to Boost Research after Hurricane Ike
HOUSTON-(Business Wire)-September 16, 2009 - Texas A&M Institute for Genomic Medicine (TIGM) – a research institute of the Texas A&M Health Science Center – has created a grant-in-aid program specifically to assist University of Texas Medical Branch at Galveston (UTMB) scientists...
67 - Internationally Acclaimed Inventor, Dean Kamen, to Receive Prestigious BioMed SA Palmaz Award for Innovation in Healthcare and the Biosciences
SAN ANTONIO-(Business Wire)-September 16, 2009 - Internationally renowned inventor, entrepreneur and thought leader, Dean Kamen of Manchester, NH, can add another prestigious award to his resume when he accepts BioMed SA’s Julio Palmaz Award for Innovation in Healthcare and the Biosciences. BioMed...
68 - Research and Markets: Principles of Genetics, Take Note!, 4th Edition
DUBLIN-(Business Wire)-September 16, 2009 - Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Principles of Genetics, Take Note!, 4th Edition" to their offering. In the rapidly advancing science of genetics, currency and accuracy are critical in any book...
69 - Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement
CAMBRIDGE, Mass.-(Business Wire)-September 16, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement...
70 - Cyntellect Launches Stem Cell Manager™ Powered by LEAP™
SAN DIEGO-(Business Wire)-September 16, 2009 - Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of Stem Cell Manager...
71 - Enzo Biochem to Present at UBS Global Life Sciences Conference
NEW YORK-(Business Wire)-September 16, 2009 - Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, announced today that Barry Weiner, President, and David...
72 - PerkinElmer Purchases GE Healthcare’s Catalog Radiochemicals, SPA Reagents and Cytostar-T Plate Assets
WALTHAM, Mass.-(Business Wire)-September 16, 2009 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and their environment, today announced that it has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay...
73 - Applied Biosystems Launches New Genomic Analysis Tools that Simplify Disease Research
CARLSBAD, Calif.-(Business Wire)-September 16, 2009 - Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the launch of genomic analysis tools that will help researchers in studies that associate genetic variation with specific diseases. These new tools, known as...
74 - Inovio Biomedical CEO to Present at MIT Technology Review Emerging Technology Conference
SAN DIEGO-(Business Wire)-September 16, 2009 - Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and...
75 - Fluidigm and Quimica Valaner Team Together in Mexican Distribution Deal
SOUTH SAN FRANCISCO, Calif. & MEXICO CITY-(Business Wire)-September 15, 2009 - Fluidigm Corporation, the inventor of integrated fluidic circuits (IFCs), has appointed Química Valaner S.A de C.V as exclusive distributor for Fluidigm’s industry-leading instrumentation and chips in Mexico...
76 - Breakthrough Genetic Test Helps Doctors Assess Risk Of Developing Psoriatic Arthritis (PsA)
IRVINE, Calif.-(Business Wire)-September 15, 2009 - The first genetic test for Psoriatic arthritis (PsA) is being launched today by PsoriasisDX, LLC, a subsidiary of molecular dermatology research and development innovator PharmaGenoma, Inc. PsA is a progressive irreversible joint disease associated...
77 - Talecris Commences Initial Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 15, 2009 - Talecris Biotherapeutics Holdings Corp. (“Talecris”) today announced the launch of its initial public offering of 44,736,842 shares of its common stock, par value $0.01 per share. Talecris is a global biotherapeutic and...
78 - Centric Health Resources Identifies Ultra-Orphan Industry Trends, Impact of Risk Evaluation and Mitigation Strategies (REMS)
CHESTERFIELD, Mo.-(Business Wire)-September 14, 2009 - Highlighting the role of specialty pharmaceuticals as the fastest growing segment of the prescription drug market in the United States, the recent Second Annual Ultra Orphan Conference: “Emerging Commercialization Strategies for Addressing the...
79 - ArQule, Inc. to Present at UBS Global Life Sciences Conference on September 21, 2009
WOBURN, Mass.-(Business Wire)-September 14, 2009 - ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the UBS Global Life Sciences Conference on Monday, September 21, 2009 at 10:30 a.m. eastern time. ArQule’s presentation will be web cast live and can be accessed through the...
80 - BioReference Laboratories, Inc to Speak at the UBS Global Life Sciences Conference
ELMWOOD PARK, N.J.-(Business Wire)-September 14, 2009 - BioReference Laboratories, Inc (NASDAQ:BRLI) announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2009 UBS Global Life Sciences Conference on Monday, September 21, 2009, at The Grand...
81 - Research and Markets: A Guide to Genetic Counseling, 2nd Edition
DUBLIN-(Business Wire)-September 14, 2009 - Research and Markets . For more information visit http://www.researchandmarkets.com/research/802501/a_guide_to_genetic
82 - Cipher Uses DSG’s EDC in Effort to Give Hope to Severe Acne Sufferers
MALVERN, Pa.-(Business Wire)-September 14, 2009 - DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s...
83 - 7 Million Babies and Children and 6 Million Hispanics in the U.S. Have Acid Reflux
WASHINGTON-(Business Wire)-September 14, 2009 - (NAPSW) The Pediatric Adolescent Gastroesophageal Reflux (PAGER) Association has been helping families learn about acid reflux since 1992. The medical name for the disease is gastroesophageal reflux. It means stomach + esophagus + backwash. “Acid...
84 - FDA and EMEA Grant Orphan Drug Designation for Antisense Pharma's Investigational Drug Trabedersen in Pancreatic Carcinoma
REGENSBURG, Germany-(Business Wire)-September 14, 2009 - The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug...
85 - Osiris Therapeutics to Present at ThinkEquity and UBS Conferences
COLUMBIA, Md.-(Business Wire)-September 11, 2009 - Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D...
86 - ACAM Partners with Jonathan Wright, MD and Daved Rosensweet, MD to Produce Comprehensive Hormone Seminar
IRVINE, Calif.-(Business Wire)-September 11, 2009 - The American College for Advancement in Medicine (ACAM) announced today that it will co-produce a seminar with Johnathan Wright, MD and Daved Rosensweet, MD titled “Female & Male Endocrine Seminar: Enhancing the vitality of your patients with...
87 - Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
CAMBRIDGE, Mass.-(Business Wire)-September 11, 2009 - Genzyme Corporation (Nasdaq: GENZ) reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years...
88 - Data Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
DUSSELDORF, Germany-(Business Wire)-September 11, 2009 - Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI...
89 - LabCorp is Scheduled to Present at the UBS 2009 Global Life Sciences Conference
BURLINGTON, N.C.-(Business Wire)-September 11, 2009 - Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the UBS 2009 Global Life Sciences Conference in New York City, NY. LabCorp’s...
90 - BioMarker Strategies Raises $1.7 Million, Including Investment by Abell Foundation
BALTIMORE-(Business Wire)-September 11, 2009 - BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the...
91 - New Ohio Bioscience Resource Directory Keeps Pace with Industry Sector’s Growth
COLUMBUS, Ohio-(Business Wire)-September 10, 2009 - BioOhio and the Global Cardiovascular Innovation Center (GCIC) have launched an expanded and improved Ohio Bioscience Resource Directory, the most comprehensive online collection of Ohio companies, organizations, and research centers involved in...
92 - American Diversified Holdings Corporation to Be Featured Presenter at the International Stem Cell Network's New York City Symposium
DEL MAR, Calif.-(Business Wire)-September 10, 2009 - Ernest B. Remo, Chairman/CEO of American Diversified Holdings Corporation (Pink Sheets:ADHC) announced that the company will be a featured presenter at a symposium sponsored by the International Stem Cell Network scheduled for the week of...
93 - Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Morgan Stanley Conference
ROCKVILLE, Md.-(Business Wire)-September 10, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2009 Morgan Stanley Global Healthcare Unplugged Conference will be webcast and may be accessed at www.hgsi.com A member of Human Genome Sciences’ senior...
94 - Scarab Genomics and NeoClone Have Entered Into License Agreement for Antibodies Against Shiga Toxin
MADISON, Wis.-(Business Wire)-September 10, 2009 - Scarab Genomics, a leader in E coli technology, has entered into a license agreement with NeoClone to market and distribute their proprietary antibodies against Shiga toxin. “We are confident the research and diagnostic markets will welcome access...
95 - Reliability and Validity of Dyax’s Novel Patient Reported Outcome Measures (PROs) Affirmed in Published Study
CAMBRIDGE, Mass.-(Business Wire)-September 10, 2009 - Dyax Corp. (NASDAQ:DYAX) today announced a study published evaluating the Company’s novel Patient Reported Outcome Measures (PROs) used to assess hereditary angioedema (HAE) attacks affirmed the PROs as valuable instruments in capturing HAE...
96 - ChinaBio® Day Unveils Program Highlights
CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 10, 2009 - EBD Group and ChinaBio® LLC, today unveiled program highlights for the ChinaBio® Day event to be held on September 15, 2009 at the San Francisco Marriott. In the heart of the American biotech industry, this unique event will...
97 - Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.-(Business Wire)-September 9, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2009, at 3:20 p.m. ET...
98 - LifeCell Dx & E-Fertility Gives New Hope to Millions of Couples
BUFFALO, N.Y.-(Business Wire)-September 9, 2009 - LifeCell Dx, a new medical diagnostic company specializing in male infertility, offers new hope for couples facing uncertain parenthood. Couples concerned about male fertility potential might explore the e-diagnostic and Internet options being...
99 - New Promega Maxwell® 16 Viral Kit Performs Viral Purification for Labs in Mexico
MADISON, Wis.-(Business Wire)-September 9, 2009 - Promega announces the release of the Maxwell® 16 Viral Total Nucleic Acid Purification Kit which, among other labs, currently serves the OCA Hospital in Mexico for H1N1 clinical research. OCA, the largest private hospital in Monterrey Mexico...
100 - NATURE REVIEWS DRUG DISCOVERY Publishes Epizyme-authored Paper on Protein Methyltransferases
CAMBRIDGE, Mass.-(Business Wire)-September 9, 2009 - A paper underscoring the importance of protein methyltransferases (PMTs) in drug discovery is published in the September 2009 online issue of NATURE REVIEWS DRUG DISCOVERY. Scientists Dr. Robert A. Copeland and Dr. Victoria M. Richon from Epizyme...
101 - Enzo Biochem to Present at Thomas Weisel Partners 2009 Healthcare Conference
NEW YORK-(Business Wire)-September 9, 2009 - Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, announced today that Barry Weiner, President, and David...
102 - Constellation Pharmaceuticals Appoints Renowned Cancer Biologist Edward E. Harlow, Jr., Ph.D. as Company’s CSO
CAMBRIDGE, Mass.-(Business Wire)-September 9, 2009 - Constellation Pharmaceuticals, Inc. today announced that it has appointed Edward E. Harlow, Jr., Ph.D. as the company’s Chief Scientific Officer. This appointment reflects the Company’s strong scientific heritage and its progress in building...
103 - Complete Genomics Demonstrates Its Technology’s Potential by Sequencing 14 Human Genomes for Customers
MOUNTAIN VIEW, Calif.-(Business Wire)-September 9, 2009 - Complete Genomics Inc., a third-generation human genome sequencing company, announced today that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009. Considering that fewer than 20 genomes have been...
104 - Inspire Wins North Carolina Health & Life Sciences Award for Cystic Fibrosis Development Program
DURHAM, N.C.-(Business Wire)-September 9, 2009 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF). This award...
105 - Cytori Therapeutics Announces Fall U.S. Medical Conference Presentation Schedule; Interim RESTORE-2 Results to be Reported in December
SAN DIEGO-(Business Wire)-September 9, 2009 - Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today its fall medical conference presentation schedule. The Company will present clinical and preclinical results on the use of adipose tissue-derived stem and regenerative cells or will be exhibiting at...
106 - Neuralstem Receives Notice of Patent Allowance
ROCKVILLE, Md.-(Business Wire)-September 9, 2009 - Neuralstem, Inc. (NYSE Amex: CUR) today announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative...
107 - Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update
PHILADELPHIA & REHOVOT, Israel-(Business Wire)-September 8, 2009 - Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and six months ended June 30, 2009. Highlights of the second quarter of 2009 and...
108 - Biogen Idec Reiterates Proposal to Acquire All Outstanding Shares of Facet for $14.50 Per Share in Cash
CAMBRIDGE, Mass.-(Business Wire)-September 8, 2009 - Biogen Idec Inc. (NASDAQ:BIIB) today reiterated its proposal to acquire all of the outstanding shares of Facet Biotech Corporation for $14.50 per share in cash. James C. Mullen, Biogen Idec’s President and Chief Executive Officer, stated...
109 - Exact Sciences to Present at Baird, Rodman & Renshaw Conferences
MADISON, Wis.-(Business Wire)-September 8, 2009 - Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present at Robert W. Baird & Co.’s 2009 Health Care Conference, which is being held Sept. 9-10, at the Four Seasons Hotel in New York, and the Rodman & Renshaw Annual Global...
110 - Response Genetics, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
LOS ANGELES-(Business Wire)-September 8, 2009 - Response Genetics, Inc. (Nasdaq:RGDX) announced today that its president and CEO, Kathleen Danenberg, will present at the Rodman & Renshaw 11th Annual Healthcare Conference at 5:20 p.m. on Thursday, September 10. The conference is being held at the...
111 - Amerinet Named Provider of Choice by National Rural Health Association Partnership
ST. LOUIS-(Business Wire)-September 8, 2009 - In recognition of their commitment to helping rural healthcare providers reduce costs and improve quality, Amerinet, a leading national healthcare group purchasing organization, has been named a “Provider of Choice” by the National Rural Health...
112 - Enzo Biochem Appoints Dr. Mohan Chellani, 15-Year Industry Veteran, Vice President of Scientific Affairs at Enzo Clinical Labs
NEW YORK-(Business Wire)-September 8, 2009 - Enzo Biochem, Inc. (NYSE:ENZ) today announced the appointment of Mohan Chellani, Ph.D., formerly a senior manager with Quest Diagnostics, as Vice President of Scientific Affairs at its Enzo Clinical Labs subsidiary. He will oversee all aspects of the...
113 - StemCells, Inc. to Present at Two Investor Conferences in September
PALO ALTO, Calif.-(Business Wire)-September 8, 2009 - StemCells, Inc. (NASDAQ:STEM) announced today that President and Chief Executive Officer Martin McGlynn will present an update on the Company’s programs and operations at the Thomas Weisel Partners Healthcare Conference 2009 on Friday...
114 - CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial for ALS
LOS ANGELES-(Business Wire)-September 8, 2009 - CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its...
115 - LabCorp is Scheduled to Present at the Bank of America Merrill Lynch Global Healthcare Conference
BURLINGTON, N.C.-(Business Wire)-September 8, 2009 - Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch Global Healthcare Conference in London, United...
116 - Cell Biosciences Signs Agreement to Acquire Alpha Innotech
SANTA CLARA, Calif.-(Business Wire)-September 8, 2009 - Cell Biosciences, Inc. and Alpha Innotech Corp. (OTC BB: APNO.OB) today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9...
117 - PerkinElmer Announces Acquisition of Prenatal and Newborn Screening Laboratory in India
CHENNAI, India-(Business Wire)-September 8, 2009 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and their environment, today announced that it has acquired the genetic screening business of Surendra Genetic Labs, Pvt Ltd., a leading laboratory in India that...
118 - BrainStorm Cell Therapeutics to Address Shareholders via a Webcast Audio Conference
NEW YORK & PETACH TIKVAH, Israel-(Business Wire)-September 8, 2009 - BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI) , announced today that its senior management will address shareholders in a webcast audio conference. Shareholders are welcome to submit questions in advance of the webcast to...
119 - RiNA GmbH Acquires Roche RTS Protein Expression Portfolio
PENZBERG, Germany-(Business Wire)-September 8, 2009 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009. RiNA will contribute its longstanding experience in...
120 - Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
COLUMBIA, Md.-(Business Wire)-September 8, 2009 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation...
121 - Enzo Biochem to Present at Rodman & Renshaw Annual Global Investment Conference
NEW YORK-(Business Wire)-September 8, 2009 - Enzo Biochem, Inc. (NYSE: ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, announced today that Barry Weiner, President, and David...
122 - Helicos Sells Multiple HeliScope™ Sequencers to RIKEN Institute
CAMBRIDGE, Mass.-(Business Wire)-September 8, 2009 - Helicos BioSciences Corporation (NASDAQ:HLCS) today announced that the RIKEN Yokohama Institute Omics Science Center (OSC) has agreed to purchase four Helicos™ Genetic Analysis Systems. The transaction represents the first multisystem sale of...
123 - FDA and BioTrove Collaborate to Evaluate BioTrove’s Novel Genetic Profiling and Pathogen Detection System for Possible Use in Detecting Threats to the Nation’s Blood Supply
WOBURN, Mass.-(Business Wire)-September 8, 2009 - BioTrove announced a collaboration with the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research to investigate the utility of the company’s Standardized NanoArray PCR (SNAP) gene expression profiling system for the...
124 - Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash
CAMBRIDGE, Mass.-(Business Wire)-September 4, 2009 - Biogen Idec Inc. (NASDAQ:BIIB) today announced that it has submitted a proposal to the Board of Directors of Facet Biotech Corporation (NASDAQ:FACT) to acquire all of the outstanding shares of Facet for $14.50 per share in cash. The all-cash offer...
125 - Bio-Computing Day at SC09 to Feature One of the World’s Leading Scientists in Molecular Biotechnology and Genomics
PORTLAND, Ore.-(Business Wire)-September 4, 2009 - SC09, the 22nd annual event in the SC conference series, recognized globally as the premier international conference on high performance computing, networking, storage and analysis, announced today it has selected world renowned Biologist, Dr. Leroy...
126 - Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
ROCKVILLE, Md.-(Business Wire)-September 4, 2009 - Human Genome Sciences, Inc. (NASDAQ:HGSI) announced today that its presentation at the 2009 Thomas Weisel Partners Healthcare Conference will be webcast and may be accessed at www.hgsi.com. A member of Human Genome Sciences’ senior management team...
127 - DDN Exec Orchestrates Local Prescription Drug Collection Effort
MENOMONEE FALLS, Wis.-(Business Wire)-September 3, 2009 - In an effort to keep unused prescription drugs out of the hands of pre-teens and teenagers, DDN executive Joe Otto enlisted the support of Menomonee Falls Police Chief Anna Ruzinski, Community Memorial Hospital, and his company. As a...
128 - Luminex Receives 510(K) Clearance for New Cystic Fibrosis Test
AUSTIN, Texas-(Business Wire)-September 3, 2009 - Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic...
129 - Alnylam to Webcast Presentations at the Rodman & Renshaw Global Investment Conference and the Thomas Weisel Partners Healthcare Conference 2009
CAMBRIDGE, Mass.-(Business Wire)-September 3, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Rodman & Renshaw Global Investment Conference on Thursday, September 10, 2009, at 2:00...
130 - New Promega GoTaq® qPCR Master Mix Excels in Sensitivity and Stability
MADISON, Wis.-(Business Wire)-September 3, 2009 - Now real-time PCR methods can detect even smaller changes and rare events with the new Promega GoTaq qPCR Master Mix. The new GoTaq qPCR Master Mix frequently delivers earlier cycle thresholds than SYBR® Green I. The advanced functionality gives...
131 - Bayer CropScience and Precision BioSciences Inc. Collaborate to Create Site-Specific Genome Modifications in Plants
MONHEIM, Germany-(Business Wire)-September 3, 2009 - Bayer CropScience and Precision BioSciences Inc., a biotechnology company headquartered in Research Triangle Park, NC, USA, announced today that they have entered into a collaborative agreement to create site-specific genome modifications in...
132 - StemCells, Inc. Demonstrates Protection of Neurological Function in Batten Mouse
PALO ALTO, Calif.-(Business Wire)-September 3, 2009 - StemCells, Inc. (NASDAQ:STEM) today announced the publication of preclinical data demonstrating for the first time that transplantation of its proprietary, purified human neural stem cells delays the loss of motor function in a mouse model of...
133 - WellGen, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
NORTH BRUNSWICK, N.J.-(Business Wire)-September 3, 2009 - WellGen, Inc. (www.wellgen.com), a private biotechnology company that is discovering and developing proprietary medical foods using nutrigenomics technology, announced that Dr. Roddy Carter, president and chief executive officer, will present...
134 - Illumina to Present at Upcoming Investment Conferences in September
SAN DIEGO-(Business Wire)-September 3, 2009 - Illumina, Inc. (NASDAQ:ILMN) today announced that the Company will webcast its presentations at three upcoming investment conferences. Illumina will webcast its presentation at the Thomas Weisel Partners Healthcare Conference in Boston, Massachusetts...
135 - XDx to Present at the Thomas Weisel 2009 Healthcare Conference
BRISBANE, Calif.-(Business Wire)-September 3, 2009 - XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced that Pierre Cassigneul, president and chief executive officer, is scheduled to present at the...
136 - Neurologix to Present at Rodman & Renshaw 11th Annual Healthcare Conference
FORT LEE, N.J.-(Business Wire)-September 3, 2009 - Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that it is scheduled to present at the Rodman & Renshaw 11th Annual...
137 - Curis Announces GDC-0449 Phase I Clinical Data Published in New England Journal of Medicine
CAMBRIDGE, Mass.-(Business Wire)-September 3, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the...
138 - Dyax Corp. to Present at Four Investor Conferences in September
CAMBRIDGE, Mass.-(Business Wire)-September 3, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer, and other senior management of Dyax will present at four investor...
139 - SuperGen to Present at September Investment Conferences
DUBLIN, Calif.-(Business Wire)-September 3, 2009 - SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., President and Chief Executive Officer, will present at two upcoming...
140 - Enabling Capabilities of Inovio Biomedical’s Electroporation Delivery Technology with SIV DNA Vaccine Confirmed in Collaborative Study With National Cancer Institute
SAN DIEGO-(Business Wire)-September 3, 2009 - Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that data generated from a pre-clinical collaborative study by National Cancer Institute (NCI) and Inovio scientists were published...
141 - NeoMatrix to Sponsor Congressional Event on Young Women and Breast Cancer
WASHINGTON-(Business Wire)-September 2, 2009 - NeoMatrix, makers of the HALO™ Breast Pap Test, is a sponsor of a congressional reception Sept. 9 on Capitol Hill, which will focus on the EARLY Act and raising awareness about young women’s breast cancer risk. Among the speakers at the event will...
142 - Rosetta Genomics to Hold Second Quarter Conference Call on September 8
REHOVOT, Israel & PHILADELPHIA-(Business Wire)-September 2, 2009 - Rosetta Genomics (NASDAQ: ROSG) today announced it will release financial results for the second quarter of 2009 on September 8, 2009 after the close of NASDAQ trading, and will host a conference call and webcast to discuss those...
143 - Rosetta Genomics to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
PHILADELPHIA & REHOVOT, Israel-(Business Wire)-September 2, 2009 - Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced that Amir Avniel, president and chief executive officer, will be presenting a corporate update at the Rodman &...
144 - Dicerna Pharmaceuticals to Present at Upcoming Conferences
WATERTOWN, Mass.-(Business Wire)-September 2, 2009 - Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNAi molecules, today announced that James C. Jenson...
145 - Ikonisys to Present at the Thomas Weisel Partners Healthcare Conference 2009
NEW HAVEN, Conn.-(Business Wire)-September 2, 2009 - Ikonisys announced today that Dr. Petros Tsipouras, Chairman and Chief Executive Officer, will present at the Thomas Weisel Partners Healthcare Conference 2009. Presentation details are as follows: Date: Friday, September 11, 2009 Time...
146 - Curis to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
CAMBRIDGE, Mass.-(Business Wire)-September 2, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Rodman & Renshaw 11th Annual...
147 - Receptor Logic, Inc. Awarded National Cancer Institute Grant
ABILENE, Texas & OKLAHOMA CITY-(Business Wire)-September 2, 2009 - Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm...
148 - Life Technologies to Sell Mass Spectrometry Business to Danaher for $450 Million in Cash
CARLSBAD, Calif.-(Business Wire)-September 2, 2009 - Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in...
149 - FDA Advisory Committee Recommends Randomized Trial to Support Proposed Indication for Clolar in Adult AML
CAMBRIDGE, Mass.-(Business Wire)-September 1, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult...
150 - Dyax Corp. Announces Expanded Roles for Two Senior Management Executives as Company Advances Commercialization Plan
CAMBRIDGE, Mass.-(Business Wire)-September 1, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that two senior executives will be taking on expanded roles reflecting the Company’s continued growth and plans for commercialization...
151 - Strategic Product Development Expert to Educate Utah Technology Company Executives
SALT LAKE CITY-(Business Wire)-September 1, 2009 - The Utah Technology Council (UTC), Utah’s premier professional organization, today announced that Dr. Steven Wheelwright will speak on “Leadership and Growth through Product Development” at its annual educational event on Sept. 10, from...
152 - Metabasis Therapeutics Announces the Resignation of Mark Erion, Ph.D., Metabasis’ President, CEO & CSO
SAN DIEGO-(Business Wire)-September 1, 2009 - Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that Mark Erion, PhD, the Company’s president, chief executive officer and chief scientific officer as well as a member of its board of directors, has resigned as an officer and director of the...
153 - Prof. Offen to Discuss Latest Progress of Brainstorm Today on Israeli National Radio
NEW YORK & PETACH TIKVAH, Israel-(Business Wire)-September 1, 2009 - BrainStorm Cell Therapeutics (OTCBB:BCLI), announces that Prof. Daniel Offen – Brainstorm’s Chief Scientist will be interviewed today, September 1st between 08:00-09:00 AM EST on Reshet Bet, the Israeli national...
154 - Intrexon Announces Purchase of Industry-Leading Bioassay Operation
BLACKSBURG, Va.-(Business Wire)-September 1, 2009 - Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned...
155 - Bio-Matrix Scientific Group Inc. Chairman Comments on New Opportunities for both the Company and Its Majority Owned Subsidiary Entest BioMedical Inc.
SAN DIEGO-(Business Wire)-September 1, 2009 - Bio-Matrix Scientific Group, Inc. (OTCBB:BMSN) Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property. Mr. Koos noted, “In the last 3 months we have made...
156 - Gene Signal and Collaborators Publish GS-101 Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth
LAUSANNE, Switzerland-(Business Wire)-September 1, 2009 - Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops...
157 - Illumina Announces Delivery of the First Genome Through Its Individual Genome Sequencing Service
SAN DIEGO-(Business Wire)-August 31, 2009 - Illumina, Inc. (NASDAQ:ILMN) today announced that it has delivered Hermann Hauser’s genome sequence. Dr. Hauser, Partner, Amadeus Capital Partners Ltd, is the first consumer to purchase Illumina’s individual genome sequencing service working with his...
158 - BrainStorm Cell Therapeutics Enters into Agreement for Clinical-Grade Stem Cell Production for ALS
NEW YORK & PETACH TIKVAH, Israel-(Business Wire)-August 31, 2009 - BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading...
159 - Celladon Corporation and Momentum Research Complete Enrollment of MYDICAR® Phase 2 Study of First-in-Human Gene Transfer to Treat Patients with Advanced Heart Failure
SAN DIEGO-(Business Wire)-August 31, 2009 - Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is...
160 - DNA Vaccine Company Inovio Biomedical to Present at Rodman & Renshaw Investor Healthcare Conference
SAN DIEGO-(Business Wire)-August 31, 2009 - Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that the company's President and Chairman of the Board, Avtar Dhillon, MD, will present at Rodman & Renshaw’s 11th Annual...
161 - FDA Advisory Committee to Discuss Genzyme’s Clolar for Adult AML on September 1
CAMBRIDGE, Mass.-(Business Wire)-August 28, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring...
162 - First Human Immunology Challenge Symposium Announced by NIH’s National Heart, Lung and Blood Institute’s (NHLBI) Center for Human Immunology (CHI)
BETHESDA, Md.-(Business Wire)-August 27, 2009 - NIH’s National Heart, Lung and Blood Institute’s CENTER FOR HUMAN IMMUNOLOGY (CHI) announces the first Meeting the Human Immunology Challenge Symposium. This two-day meeting will be held September 3-4, 2009 on the NIH Campus. This symposium is...
163 - Ligand to Present at Thomas Weisel Partners on September 9
SAN DIEGO-(Business Wire)-August 26, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John L. Higgins, President and Chief Executive Officer, will be presenting at the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9, at 9:10 a.m. Eastern...
164 - Fluidigm: 250 Million Microfluidic Valves Manufactured -- and Counting
SINGAPORE-(Business Wire)-August 26, 2009 - Fluidigm today announced that its Singapore biochip factory has manufactured and shipped more than 250 million microscopic NanoFlex™ valves. The 250 million valves built into Fluidigm’s integrated fluidic circuits (IFCs) would be equivalent to the...
165 - BioReference Laboratories, Inc. Announces Earnings Date for Third Quarter for Fiscal Year 2009
ELMWOOD PARK, N.J.-(Business Wire)-August 26, 2009 - BioReference Laboratories, Inc. (NASDAQ: BRLI) announced today it plans to issue earnings results for the third quarter of fiscal 2009 before the open of market trading on Wednesday, September 2, 2009. The Company’s earnings conference call is...
166 - Roche xCELLigence System for Cell Analysis to Provide Predictive Mechanistic Information for Small Molecule Compounds
PENZBERG, Germany-(Business Wire)-August 26, 2009 - The extent to which protein targets are modulated by drugs or small molecule compounds depends on a number of factors, including the expression levels of the target, the effective concentration of the compound, and the time needed for the...
167 - Dyax Announces Developments in Licensing and Funded Research Program
CAMBRIDGE, Mass.-(Business Wire)-August 26, 2009 - Dyax Corp. (NASDAQ:DYAX) announced today successful advancement into Phase 1 clinical trials of two candidates identified using Dyax’s proprietary phage display technology by licensees of the Company’s Licensing and Funded Research Program...
168 - Sunquest, Partners HealthCare System and Massachusetts General Hospital Announce Agreement to Co-Develop Next Generation Diagnostic Pathology Solutions
TUCSON, Ariz.-(Business Wire)-August 26, 2009 - Sunquest Information Systems, Inc., a market leader in laboratory and diagnostic information systems, the Massachusetts General Hospital (MGH), an innovator in medical care, research and teaching, and Partners HealthCare System, an integrated health...
169 - IBM Chief Economist Philip Swan to Discuss Key Worldwide Economic Trends at UTC Special Breakfast Event
SALT LAKE CITY-(Business Wire)-August 25, 2009 - The Utah Technology Council (UTC), Utah’s premier professional organization, announced that IBM chief economist Dr. Philip L. Swan will be the featured presenter at a special UTC industry breakfast event, “Moving Forward in Today’s Economy...
170 - LabConnect Appoints Chief Operating Officer
SEATTLE-(Business Wire)-August 25, 2009 - LabConnect, LLC, today announced the appointment of Frank D. Morrow, Ph.D., FACN, as its chief operating officer. Dr. Morrow is a veteran of the central lab business, having served as founding executive, president and chief scientific officer at Quintiles...
171 - Illumina Announces $75 Million Share Repurchase Program
SAN DIEGO-(Business Wire)-August 24, 2009 - Illumina, Inc. (NASDAQ:ILMN) today announced that its Board of Directors has approved a new stock repurchase program, authorizing the Company to repurchase in the aggregate up to $75 million of its outstanding common stock. The Company has terminated the...
172 - PacifiCord to Offer Free Prenatal Classes in San Diego
IRVINE, Calif.-(Business Wire)-August 24, 2009 - Dedicated to serving the private cord blood banking needs of Southern California, PacifiCord (www.pacificord.com) today announced it will be offering free prenatal classes in San Diego starting September 9, 2009. This will be PacifiCord’s fourth...
173 - HiFi DNA President Challenges NCI Endorsement of Inaccurate HPV Tests for Referring Women to Unnecessary and Costly Cervical Biopsies
TRUMBULL, Conn.-(Business Wire)-August 24, 2009 - A National Cancer Institute (NCI) investigator’s endorsement of inaccurate high-risk HPV test to refer women to cervical cancer tests, despite the weak evidence of its value, is “unfortunate and inappropriate.” Sin Hang Lee, MD, president of...
174 - Researchers at Signature Genomic Laboratories Identify Likely Causative Gene for New Genetic Disorder
SPOKANE, Wash.-(Business Wire)-August 24, 2009 - Researchers at Signature Genomic Laboratories, which performs diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, recently identified what is likely to be the causative gene...
175 - Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin Lymphoma
BOTHELL, Wash.-(Business Wire)-August 24, 2009 - Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC...
176 - Fresenius Medical Care Gives Dialysis Patients Freedom To Travel This Fall and Winter
WALTHAM, Mass.-(Business Wire)-August 24, 2009 - As thousands of people plan getaways for the fall and winter travel seasons, easy access to healthcare is a concern for many travelers with chronic health conditions who require life-sustaining treatments. Twenty-six million Americans suffer from...
177 - Complete Genomics Secures $45 Million in Series D Funding; Appoints Two New Directors
MOUNTAIN VIEW, Calif.-(Business Wire)-August 24, 2009 - Complete Genomics Inc., a third-generation human genome sequencing company, announced that it has raised $45 million in private equity financing and closed its Series D funding round with two new investors — Essex Woodlands Health Ventures...
178 - BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
NEW YORK & PETACH TIKVAH, Israel-(Business Wire)-August 24, 2009 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for...
179 - 454 Sequencing Identifies Early Stage HIV Drug Resistance-- Low-level Mutations may have Significant Impact on Clinical Outcomes
BRANFORD, Conn-(Business Wire)-February 17, 2009 - A research study published online this week in the Journal of Infectious Disease reports that HIV resistance mutations present in as little as 1% of the viral population have a significant impact on clinical outcomes. The paper outlines the...
180 - Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells
NEW YORK-(Business Wire)-February 17, 2009 - Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Racheli Ofir, Ph.D., Senior...
181 - RainDance Technologies Appoints Patrick Kelly As European Sales Director
LEXINGTON, Mass.-(Business Wire)-February 16, 2009 - RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, has appointed Patrick Kelly to the newly created position of European Sales Director, effective immediately. “Mr...
182 - Gene Logic Announces Launch of Illumina SNP Genotyping Services
GAITHERSBURG, Md.-(Business Wire)-February 16, 2009 - Gene Logic, an Ocimum Biosolutions company, the leading integrated genomics service provider, has expanded its range of service offerings with the purchase of an Illumina iScan system. The system will be used with the recently released high...
183 - Applied Biosystems and Baylor College of Medicine Summarize Contributions to First Data Release of 1000 Genomes Project
CARLSBAD, Calif.-(Business Wire)-February 16, 2009 - Applied Biosystems, a division of Life Technologies (NASDAQ:LIFE), and scientists from the Baylor College of Medicine Human Genome Sequencing Center (HGSC), today summarized their collective contribution to the first data release of the 1000...
184 - Research and Markets: Biomarkers - Technologies, Markets and Companies
DUBLIN, Ireland-(Business Wire)-February 16, 2009 - Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biomarkers - Technologies, Markets and Companies" to their offering. This report follows the broad definition of a biomarker as a characteristic that can be...
185 - Research and Markets: Who Owns You? The Corporate Gold Rush to Patent Your Genes
DUBLIN, Ireland-(Business Wire)-February 16, 2009 - Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Who Owns You? The Corporate Gold Rush to Patent Your Genes" to their offering. Surely you own your own genes, don't you? Think again. Now that the race to...
186 - Research and Markets: A Comprehensive Analysis of the Worldwide Markets for Gene Amplification Technologies in Millions of US$
DUBLIN, Ireland-(Business Wire)-February 16, 2009 - Research and Markets has announced the addition of the "Gene Amplification Technologies - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Gene Amplification Technologies in Millions of US...
187 - Response Genetics Increasing Efficiency and Capacity of Its U.S.-Based, CLIA-Certified Laboratory in Anticipation of Increased Demand for Its ResponseDX Genetic Testing Services by Consolidating External Laboratory Facility
LOS ANGELES-(Business Wire)-February 13, 2009 - Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that the Company intends to increase the efficiency and capacity of its U.S.-based, CLIA-certified laboratory...
188 - BIO-Europe Spring® 2009 Announces Program Highlights
CARLSBAD, Calif., ZURICH & MILAN-(Business Wire)-February 13, 2009 - EBD Group announced today that the third annual BIO-Europe Spring® partnering event, March 16–18, 2009 at the Milano Convention Centre (MIC), Milan, Italy, will host many of the biggest names in biotech. Featured on panels...
189 - VGX Pharmaceuticals Announces Filing of Device Master File Amendment with the FDA for CELLECTRA Device – Intradermal Electroporation (ID-EP)
BLUE BELL, Pa.-(Business Wire)-February 13, 2009 - VGX Pharmaceuticals today announced the filing of a Device Master File (MAF) amendment with the U.S. Food and Drug Administration (FDA) for its patented CELLECTRA® adaptive constant current electroporation device for use with intradermal...
190 - Expression Analysis Enters into a Partnership with Complement Genomics Ltd to Offer Genomic Services in the United Kingdom
DURHAM, N.C.-(Business Wire)-February 13, 2009 - Expression Analysis, Inc., a leading provider of genomic services for clinical trials and research has entered into a partnership with Sunderland based Complement Genomics Ltd. (www.geneblitz.com) to offer its genomic services to the UK market. By...
191 - LabCorp is the First National Commercial Lab to Offer Roche’s COBAS® AmpliPrep/COBAS® TaqMan® HCV Test
BURLINGTON, N.C.-(Business Wire)-February 12, 2009 - Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announces that it is the first national clinical laboratory to offer HCV PCR testing using a newly FDA approved assay, the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test. This...
192 - Clinical Data, Inc. To Present at the Roth 21st Annual OC Growth Stock Conference
NEWTON, Mass.-(Business Wire)-February 12, 2009 - Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the ROTH 21st Annual OC Growth Stock Conference on Tuesday, February 17, 2009 at The...
193 - Curis Announces Genentech’s Initiation of Pivotal Phase II Trial of GDC-0449 in Advanced Basal Cell Carcinoma
CAMBRIDGE, Mass.-(Business Wire)-February 12, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech treated the first patient in a pivotal Phase II clinical...
194 - Signature Microarray Covers Regions of the Genome Associated with Schizophrenia
SPOKANE, Wash.-(Business Wire)-February 12, 2009 - Signature Genomic Laboratories’ flagship microarray, the SignatureChip®, covers regions of the human genome that were known and recently published to be associated with susceptibility to schizophrenia. A study led by investigators from Duke...
195 - Cystinosis Research Foundation Grants $425,528 to Researchers and Scientists in U.S., Europe for Rare Disease Studies
IRVINE, Calif.-(Business Wire)-February 12, 2009 - The Cystinosis Research Foundation announced it has awarded $425,528 in grants to researchers in the United States and Belgium who are working on new treatments and a cure for cystinosis, a rare, deadly metabolic disorder that afflicts about 500...
196 - Sequenom Reports Fourth Quarter Financial Results
SAN DIEGO-(Business Wire)-February 11, 2009 - Sequenom, Inc. (NASDAQ: SQNM) today reported financial results for the three and 12 months ended December 31, 2008. “This past year was pivotal for Sequenom as we continued to advance our genetic analysis and molecular diagnostics businesses,” stated...
197 - Genocea Biosciences Names Jane Halpern Vice President of Regulatory Affairs
CAMBRIDGE, Mass.-(Business Wire)-February 11, 2009 - Genocea Biosciences, a leading vaccine discovery and development company, today announced that Jane L. Halpern, Ph.D. has joined the company as Vice President of Regulatory Affairs. "Jane’s pharma industry and governmental regulatory experience...
198 - BioImagene Receives FDA 510(k) Clearance for iScan Digital Pathology Hardware
CUPERTINO, Calif.-(Business Wire)-February 11, 2009 - BioImagene, the leading provider of innovative digital pathology solutions, today announced that the company has received FDA 510(K) clearance for their PATHIAM™ System with iScan™ for assessment of HER2/neu immunohistochemistry tests. The...
199 - Pluristem Therapeutics Appoints Dr. Frida Grynspan to Vice President of Research and Development
NEW YORK-(Business Wire)-February 11, 2009 - Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today the appointment of Frida...
200 - Strong Fourth Quarter for Genzyme Concludes Productive Year
CAMBRIDGE, Mass.-(Business Wire)-February 11, 2009 - Genzyme Corp. (NASDAQ: GENZ) today announced solid fourth-quarter revenue and earnings growth and provided guidance for 2009 that underscored its positive outlook for the year. GAAP net income rose to $86.7 million, or $0.31 per diluted share...
Search Our News Using Google Search
Can't find what you want? Try using Google:
